Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Shares Outstanding (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Shares Outstanding for 9 consecutive years, with $71.0 million as the latest value for Q2 2022.

  • For the quarter ending Q2 2022, Shares Outstanding rose 0.89% year-over-year to $71.0 million, compared with a TTM value of $71.0 million through Jun 2022, up 0.89%, and an annual FY2021 reading of $70.6 million, up 1.81% over the prior year.
  • Shares Outstanding was $71.0 million for Q2 2022 at Agios Pharmaceuticals, roughly flat from $71.0 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $71.0 million in Q2 2022 and bottomed at $10.5 million in Q2 2021.
  • Average Shares Outstanding over 5 years is $62.2 million, with a median of $68.8 million recorded in 2020.
  • The sharpest move saw Shares Outstanding increased 19.24% in 2018, then tumbled 77.17% in 2021.
  • Year by year, Shares Outstanding stood at $58.2 million in 2018, then grew by 17.49% to $68.4 million in 2019, then grew by 1.31% to $69.3 million in 2020, then grew by 1.81% to $70.6 million in 2021, then rose by 0.68% to $71.0 million in 2022.
  • Business Quant data shows Shares Outstanding for AGIO at $71.0 million in Q2 2022, $71.0 million in Q1 2022, and $70.6 million in Q4 2021.